Epigenetic targeting and histone deacetylase inhibition in RCC

Swathi Ramakrishnan, Roberto Pili

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Epigenetic regulation through histone modifications and DNA methylation of critical genes involved in cell cycle regulation, invasion, metastasis, and tumor-induced angiogenesis has been shown to play an important role in cancer development. Epigenetic changes are potentially reversible and therefore represent a target for therapeutic intervention with the potential of modulating oncogenes/tumor suppressor genes involved in the initiation and progression of cancer. Rational combination strategies that take advantage of transcriptional and posttranslational modifications induced by histone deacetylase inhibitors have generated promising preclinical results and are actively being tested in clinical trials. Preclinical and clinical evidence suggests that kidney tumors are ideal candidates for epigenetic therapies in view of specific mutations in histone modifier genes, overexpression of angiogenesis factors, and intrinsic sensitivity to immunotherapies. This chapter focuses on epigenetic changes in renal cell carcinoma (RCC) and, in particular, on histone modifications and therapeutic approaches currently underway targeting these epigenetic changes.

Original languageEnglish (US)
Title of host publicationRenal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets
PublisherSpringer US
Pages193-211
Number of pages19
Volume9781461424000
ISBN (Electronic)9781461424000
ISBN (Print)1461423996, 9781461423997
DOIs
StatePublished - Nov 1 2012
Externally publishedYes

Fingerprint

Histone Deacetylases
Renal Cell Carcinoma
Epigenomics
Histone Code
Neoplasms
Modifier Genes
Histone Deacetylase Inhibitors
Angiogenesis Inducing Agents
DNA Methylation
Post Translational Protein Processing
Tumor Suppressor Genes
Oncogenes
Histones
Immunotherapy
Cell Cycle
Therapeutics
Clinical Trials
Neoplasm Metastasis
Kidney
Mutation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ramakrishnan, S., & Pili, R. (2012). Epigenetic targeting and histone deacetylase inhibition in RCC. In Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets (Vol. 9781461424000, pp. 193-211). Springer US. https://doi.org/10.1007/978-1-4614-2400-0_9

Epigenetic targeting and histone deacetylase inhibition in RCC. / Ramakrishnan, Swathi; Pili, Roberto.

Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets. Vol. 9781461424000 Springer US, 2012. p. 193-211.

Research output: Chapter in Book/Report/Conference proceedingChapter

Ramakrishnan, S & Pili, R 2012, Epigenetic targeting and histone deacetylase inhibition in RCC. in Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets. vol. 9781461424000, Springer US, pp. 193-211. https://doi.org/10.1007/978-1-4614-2400-0_9
Ramakrishnan S, Pili R. Epigenetic targeting and histone deacetylase inhibition in RCC. In Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets. Vol. 9781461424000. Springer US. 2012. p. 193-211 https://doi.org/10.1007/978-1-4614-2400-0_9
Ramakrishnan, Swathi ; Pili, Roberto. / Epigenetic targeting and histone deacetylase inhibition in RCC. Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets. Vol. 9781461424000 Springer US, 2012. pp. 193-211
@inbook{88d8378002c242a797c2903e79bb6edf,
title = "Epigenetic targeting and histone deacetylase inhibition in RCC",
abstract = "Epigenetic regulation through histone modifications and DNA methylation of critical genes involved in cell cycle regulation, invasion, metastasis, and tumor-induced angiogenesis has been shown to play an important role in cancer development. Epigenetic changes are potentially reversible and therefore represent a target for therapeutic intervention with the potential of modulating oncogenes/tumor suppressor genes involved in the initiation and progression of cancer. Rational combination strategies that take advantage of transcriptional and posttranslational modifications induced by histone deacetylase inhibitors have generated promising preclinical results and are actively being tested in clinical trials. Preclinical and clinical evidence suggests that kidney tumors are ideal candidates for epigenetic therapies in view of specific mutations in histone modifier genes, overexpression of angiogenesis factors, and intrinsic sensitivity to immunotherapies. This chapter focuses on epigenetic changes in renal cell carcinoma (RCC) and, in particular, on histone modifications and therapeutic approaches currently underway targeting these epigenetic changes.",
author = "Swathi Ramakrishnan and Roberto Pili",
year = "2012",
month = "11",
day = "1",
doi = "10.1007/978-1-4614-2400-0_9",
language = "English (US)",
isbn = "1461423996",
volume = "9781461424000",
pages = "193--211",
booktitle = "Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets",
publisher = "Springer US",

}

TY - CHAP

T1 - Epigenetic targeting and histone deacetylase inhibition in RCC

AU - Ramakrishnan, Swathi

AU - Pili, Roberto

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Epigenetic regulation through histone modifications and DNA methylation of critical genes involved in cell cycle regulation, invasion, metastasis, and tumor-induced angiogenesis has been shown to play an important role in cancer development. Epigenetic changes are potentially reversible and therefore represent a target for therapeutic intervention with the potential of modulating oncogenes/tumor suppressor genes involved in the initiation and progression of cancer. Rational combination strategies that take advantage of transcriptional and posttranslational modifications induced by histone deacetylase inhibitors have generated promising preclinical results and are actively being tested in clinical trials. Preclinical and clinical evidence suggests that kidney tumors are ideal candidates for epigenetic therapies in view of specific mutations in histone modifier genes, overexpression of angiogenesis factors, and intrinsic sensitivity to immunotherapies. This chapter focuses on epigenetic changes in renal cell carcinoma (RCC) and, in particular, on histone modifications and therapeutic approaches currently underway targeting these epigenetic changes.

AB - Epigenetic regulation through histone modifications and DNA methylation of critical genes involved in cell cycle regulation, invasion, metastasis, and tumor-induced angiogenesis has been shown to play an important role in cancer development. Epigenetic changes are potentially reversible and therefore represent a target for therapeutic intervention with the potential of modulating oncogenes/tumor suppressor genes involved in the initiation and progression of cancer. Rational combination strategies that take advantage of transcriptional and posttranslational modifications induced by histone deacetylase inhibitors have generated promising preclinical results and are actively being tested in clinical trials. Preclinical and clinical evidence suggests that kidney tumors are ideal candidates for epigenetic therapies in view of specific mutations in histone modifier genes, overexpression of angiogenesis factors, and intrinsic sensitivity to immunotherapies. This chapter focuses on epigenetic changes in renal cell carcinoma (RCC) and, in particular, on histone modifications and therapeutic approaches currently underway targeting these epigenetic changes.

UR - http://www.scopus.com/inward/record.url?scp=84949177131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949177131&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-2400-0_9

DO - 10.1007/978-1-4614-2400-0_9

M3 - Chapter

AN - SCOPUS:84949177131

SN - 1461423996

SN - 9781461423997

VL - 9781461424000

SP - 193

EP - 211

BT - Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets

PB - Springer US

ER -